Pieris Pharmaceuticals, Inc. Quarterly report [Sections 13 or 15(d)]

Fair Value Measurements - Schedule of Fair Value Measurement Key Assumptions (Details)	Mar. 31, 2025 yr	Dec. 31, 2024 yr
Discount rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative, assumption	0.20	0.20
Probability rate of achieving FDA approval of a product
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative, assumption	0.566	0.566
Expected term to FDA regulatory approval of a product
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative, assumption	2.25	2.5